8-13 For a detailed discussion of cardiovascular outcome trials (CVOTs) completed with agents from the GLP-1 RA class, please refer to the companion lesson titled: What do we Currently Know about the Cardiovascular Benefits of GLP-1 RAs
To learn all about hormone treatment from who should consider it to when to start it to how to navigate the nationwide shortage of estrogen patches we spoke with Kim Einhorn, a board-certified OB-GYN who has been practicing for 20 years and who, last year, opened the MP Collective, a concierge medicine service in Bryn Mawr dedicated to women in perimenopause and menopause
Remedy Meds ensures that medications are cold-packed for proper storage during transit
FDA Telehealth Warning Letters In early March 2026, the FDA reportedly issued warning letters to multiple telehealth companies regarding compounded GLP-1 marketing practices, with concerns including misleading marketing claims, implications of equivalence with FDA-approved drugs, and obscuring product sourcing
Baranowski BJ, Marko DM, Fenech RK, Yang AJT, MacPherson REK
I recommend using the Drug Interaction Checker to identify any potential conflicts with your GLP-1